0
POPSD-Mab Does It Amgen's osteoporosis drug met its goals, and serious infections may be less of a problem than expected. But the devil will be in the details -- it's hard to gauge the potential for the drug without more information on safety and efficacy. This is a medicine that will compete with long-marketed drugs and cheap generics. Still, this is good news for Amgen, which is why the stock is up 15% in after-hours trading. Quotes from the press release are below; click the link to read the whole thing.
Clips
Latest Pops
Latest Comments
Most Pops
Tags
Print
Save
Turn on live update